Boston Scientific Corporation filings document the regulatory record of a global medical technology company with device and therapy portfolios for cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. Recent 8-K reports furnish operating results, clinical-trial announcements and other material events tied to products such as WATCHMAN and EKOS.
Proxy and governance filings cover director elections, executive compensation, stockholder votes, board committee matters and amendments to the company’s certificate of incorporation. Additional disclosures address capital resources and financing arrangements, including revolving credit terms, along with common-stock reporting, senior debt references, risk-related governance and formal exhibits filed under the Exchange Act.
Boston Scientific Corp. (BSX) filed a Form 144 indicating a proposed sale of 2,901 common shares through Morgan Stanley Smith Barney on or after 07/29/2025. The block is valued at approximately $310,378, based on the filing’s stated aggregate market value. The shares represent an immaterial 0.0002 % of BSX’s 1.48 billion shares outstanding.
The shares were acquired as restricted stock on 05/01/2025. No other sales by the filer have occurred in the past three months, and the notice affirms the absence of undisclosed material adverse information. A Form 144 is a routine regulatory notice and does not itself execute a sale; it merely provides advance disclosure of an intent to sell restricted or control securities under Rule 144.
Given the modest dollar amount and tiny percentage of float, the transaction is unlikely to be material to Boston Scientific’s capital structure or market liquidity. Investors typically monitor such filings for insider-sentiment cues, but under Rule 144 the filer must still comply with volume, manner-of-sale, and holding-period restrictions before selling.